Madrigal Pharmaceuticals Inc(MDGL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -12.88 | Insider Own | 6.77% | Shs Outstand | 23.1M | Perf Week | -3.45% |
| Market Cap | 10.03B | Forward P/E | 76.44 | EPS next Y | 194.31% | Insider Trans | -1.41% | Shs Float | 21.5M | Perf Month | -15.39% |
| Enterprise Value | 9.54B | PEG | - | EPS next Q | -0.86 | Inst Own | 103.11% | Short Float | 11.13% | Perf Quarter | -21.23% |
| Income | -0.33B | P/S | 7.81 | EPS this Y | 53.13% | Inst Trans | -1.76% | Short Ratio | 8.12 | Perf Half Y | -15.25% |
| Sales | 1.28B | P/B | 19.15 | EPS next 5Y | - | ROA | -28.77% | Short Interest | 2.40M | Perf YTD | -25.43% |
| Book/sh | 22.68 | P/C | 11.96 | EPS past 3/5Y | 9.32% 0.37% | ROE | -53.31% | 52W High | -29.39% ($615.00) | Perf Year | 2.45% |
| Cash/sh | 36.31 | P/FCF | - | Sales past 3/5Y | - | ROIC | -37.35% | 52W Low | 10.32% ($393.61) | Perf 3Y | 244.85% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -0.28% | Gross Margin | 91.36% | Volatility(W/M) | 3.97% 3.62% | Perf 5Y | 454.51% |
| Dividend TTM | - | EV/Sales | 7.43 | Sales Y/Y TTM | 149.04% | Oper. Margin | -25.13% | ATR (14) | 17.46 | Perf 10Y | 2454.35% |
| Dividend Ex-Date | - | Quick Ratio | 2.94 | EPS Q/Q | -4.41% | Profit Margin | -25.32% | RSI (14) | 28.24 | Recom | 1.14 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.2 | Sales Q/Q | 71.17% | SMA20 | -8.63% ($475.25) | Beta | -1.02 | Target Price | $684.95 |
| Payout | - | Debt/Eq | 0.66 | Earnings | 2026/7/30 | SMA50 | -14.45% ($507.59) | Rel Volume | 0.8 | Prev Close | $453.34 |
| Employees | 915 | LT Debt/Eq | 0.66 | EPS/Sales Surpr. | 25.65% 3.46% | SMA200 | -13.5% ($502.01) | Avg Volume(3M) | 0.29M | Price | $434.24 |
| IPO | 2007/2/6 | Option/Short | Yes/Yes | Trades | 7897 | Volume | 234,853 | Change | -4.21% |
A U.S. biopharmaceutical company specializing in liver disease therapeutics, focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH) and other liver conditions. As a single-asset company, its valuation hinges almost entirely on the launch and continued prescription growth of its one core therapy.
Over the past 1 year, on the lower side
29% below its 1-year high.
Traded about as much as usual. That is 80% of its average volume.
MDGL has a sound balance sheet but weak earning power
Of every $100 in sales, $25.13 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +53.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $781. Peers typically go for $897.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +454.5%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 103.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #22 of 595 in the industry
Based on market cap of $10B.
BMRN#21 Biomarin Pharmaceutical Inc $11B PER 150.8 MDGL#22 Madrigal Pharmaceuticals Inc $10B PER - 
PCVX#23 Vaxcyte Inc $10B PER - 
CORT#24 Corcept Therapeutics Inc $9B PER 205.1 
KRYS#25 Krystal Biotech Inc $9B PER 39.0 
FAQ
What kind of company is MDGL?
MDGL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MDGL?
The market cap of MDGL is approximately $10.0B, ranking 912 within its sector.
What is the 52-week high and low for MDGL?
MDGL has recorded a 52-week high of $615.00 and a low of $393.61.
